Ocular Therapeutix (OCUL) Net Cash Flow (2013 - 2026)

Ocular Therapeutix has reported Net Cash Flow for 14 years, with the latest figure at -$70.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 65.86% year-over-year to -$70.4 million; the trailing twelve-month figure through Mar 2026 stood at $317.0 million (up 337.72% YoY), and the FY2025 full-year result was $345.0 million, up 75.87% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$70.4 million, down from $392.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $392.3 million in Q4 2025, with the low at -$70.4 million in Q1 2026.
• Average Net Cash Flow over 5 years is $29.6 million, with a median of -$18.6 million recorded in 2022.
• Peak annual rise in Net Cash Flow reached 1333.48% in 2024, while the deepest fall reached 173.89% in 2024.
• Tracing OCUL's Net Cash Flow over 5 years: stood at -$18.6 million in 2022, then jumped by 557.14% to $85.3 million in 2023, then tumbled by 141.19% to -$35.1 million in 2024, then soared by 1217.06% to $392.3 million in 2025, then sank by 117.94% to -$70.4 million in 2026.
• The last three Net Cash Flow figures came in at -$70.4 million (Q1 2026), $392.3 million (Q4 2025), and -$46.4 million (Q3 2025), per Business Quant data.

Peer Comparison